A Rapid, High-Sensitivity SARS-CoV-2 Nucleocapsid Immunoassay to Aid Diagnosis of Acute COVID-19 at the Point of Care: A Clinical Performance Study
Open Access
- 24 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Infectious Diseases and Therapy
- Vol. 10 (2), 753-761
- https://doi.org/10.1007/s40121-021-00413-x
Abstract
Introduction The LumiraDx severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen test, which uses a high-sensitivity, microfluidic immunoassay to detect the nucleocapsid protein of SARS-CoV-2, was evaluated for diagnosing acute coronavirus disease 2019 (COVID-19) in adults and children across point-of-care settings (NCT04557046). Methods Two paired anterior nasal swabs or two paired nasopharyngeal swabs were collected from each participant. Swabs were tested by the LumiraDx SARS-CoV-2 antigen test and compared with real-time polymerase chain reaction (rt-PCR; Roche cobas 6800 platform). Sensitivity, specificity and likelihood ratios were calculated. Results were stratified on the basis of gender, age, duration of symptoms, and rt-PCR cycle threshold. Results Out of the 512 participants, aged 0–90 years, of this prospective validation study, 414 (81%) were symptomatic for COVID-19 and 123 (24%) swabs were positive for SARS-CoV-2 based on rt-PCR testing. Compared with rt-PCR, the 12-min nasal swab test had 97.6% sensitivity and 96.6% specificity, and nasopharyngeal swab had 97.5% sensitivity and 97.7% specificity, within 12 days of symptom onset, representing the period of infectivity. All (100%) samples detected within 33 rt-PCR cycles were also identified using the antigen test. Results were consistent across age and gender. The user error rate of the test system when used by minimally trained operators was 0.7% (95% confidence interval [CI] 0.1–3.7%). Conclusion The rapid, high-sensitivity assay using nasopharyngeal or anterior nasal sampling may offer significant improvements for diagnosing acute SARS-CoV-2 infection in clinic- and community-based settings.Funding Information
- LumiraDx Ltd.
This publication has 20 references indexed in Scilit:
- Author Correction: Virological assessment of hospitalized patients with COVID-2019Nature, 2020
- Virological assessment of hospitalized patients with COVID-2019Nature, 2020
- Fast, portable tests come online to curb coronavirus pandemicNature Biotechnology, 2020
- Epidemiology and clinical features of COVID-19: A review of current literatureJournal of Clinical Virology, 2020
- Diagnosing COVID-19: The Disease and Tools for DetectionACS Nano, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019The New England Journal of Medicine, 2020
- Real-Time Reverse Transcription–Polymerase Chain Reaction Assay for SARS-associated CoronavirusEmerging Infectious Diseases, 2004
- SARS Virus: The Beginning of the Unraveling of a New CoronavirusJournal of Biomedical Science, 2003
- Probable Inference, the Law of Succession, and Statistical InferenceJournal of the American Statistical Association, 1927